enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD
0.763
-0.092 (-10.79%)
Feb 21, 2025, 4:00 PM EST - Market open
-10.79%
Market Cap 320.64M
Revenue (ttm) n/a
Net Income (ttm) -55.14M
Shares Out 50.98M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 48,530
Open 0.900
Previous Close 0.855
Day's Range 0.750 - 0.900
52-Week Range 0.750 - 0.900
Beta -0.65
Analysts n/a
Price Target n/a
Earnings Date Mar 13, 2025

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 57
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.